Cardiovascular biomarkers provide a non-invasive approach for the early diagnosis and prognosis of cardiovascular diseases and identifying COVID-19 patients at risk for cardiovascular complications.
This review highlights the critical role of novel and established cardiovascular biomarkers in the early, non-invasive diagnosis and prognosis of cardiovascular diseases, including in the context of COVID-19.
Cardiovascular diseases, a global health issue, claim the lives of many every year. Lifestyle changes and genetic predisposition are the key drivers for the development of CVDs. In many of the patients, the disease is detected at the end stage making heart transplantation the only treatment option. Hence every attempt should be made to identify the risk at an early stage and initiate preventive measures to improve the quality of their life. Biomarkers are one of the critical factors that aid in the early diagnosis of CVDs. More specific and highly sensitive biomarkers have been discovered lately and have been employed for prognosis and diagnosis of CVDs. The present review briefs about the various categories of cardiovascular biomarkers with emphasis on novel biomarkers and discusses the biomarkers employed for different purposes in CVDs. The biomarkers have also helped in identifying COVID-19 patients with increased risk for developing cardiovascular complications. Being non-invasive makes biomarkers advantageous over other methods for evaluating the pathophysiological status of CVDs.
Sherin Saheera (Wed,) conducted a review in Cardiovascular diseases. Cardiovascular biomarkers was evaluated. Cardiovascular biomarkers provide a non-invasive approach for the early diagnosis and prognosis of cardiovascular diseases and identifying COVID-19 patients at risk for cardiovascular complications.